Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation

European Respiratory Journal

Volumn 37, Issue 1, 2011, Pages 44-52

  Edlmayr, J ^a   Niespodziana, K ^a   Popow Kraupp, T ^b   Krzyzanek, V ^d   Focke Tejkl, M ^a   Blaas, D ^c   Grote, M ^d   Valenta, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Asthma; Common cold; Rhinovirus; Vaccine

Indexed keywords

RECOMBINANT PROTEIN; VIRUS PROTEIN;

ACUTE DISEASE; ANTIBODY PRODUCTION; ARTICLE; ASTHMA; COMMON COLD; CROSS PROTECTION; DISEASE EXACERBATION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HUMAN RHINOVIRUS; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOGOLD ELECTRON MICROSCOPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RESPIRATORY TRACT DISEASE; SURFACE PROPERTY; UPPER RESPIRATORY TRACT; VACCINATION; VIRUS CAPSID; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS STRAIN;

ANIMALS; ANTIBODIES; ASTHMA; CAPSID; COMMON COLD; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HELA CELLS; HUMANS; MICE; NEUTRALIZATION TESTS; PEPTIDES; PLASMIDS; RABBITS; RECOMBINANT PROTEINS; RHINOVIRUS; SURFACE PROPERTIES; VIRAL PROTEINS;

EID: 79251554655     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00149109     Document Type: Article

References (46)

1. Holgate ST. Rhinoviruses in the pathogenesis of asthma: the bronchial epithelium as a major disease target. J Allergy Clin Immunol 2006; 118: 587-590.
2. Wos M, Sanak M, Soja J, et al. The presence of rhinovirus in lower airways of patients with bronchial asthma. Am J Respir Crit Care Med 2008; 177: 1082-1089.
3. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618-1623. (Pubitemid 33124148)
4. Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003; 58: 37-42. (Pubitemid 36135356)
5. Wat D, Gelder C, Hibbitts S, et al. The role of respiratory viruses in cystic fibrosis. J Cyst Fibros 2008; 7: 320-328.
6. Abzug MJ, Beam AC, Gyorkos EA, et al. Viral pneumonia in the first month of life. Pediatr Infect Dis J 1990; 9: 881-885.
7. Nicholson KG, Kent J, Hammersley V, et al. Risk factors for lower respiratory complications of rhinovirus infections in elderly people living in the community: prospective cohort study. BMJ 1996; 313: 1119-1123.
8. Gerna G, Piralla A, Rovida F, et al. Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients. J Med Virol 2009; 81: 1498-1507.
9. Mackay IM. Human rhinoviruses: the cold wars resume. J Clin Virol 2008; 42: 297-320.
10. Palmenberg AC, Spiro D, Kuzmickas R, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 2009; 324: 55-59.
11. Ledford RM, Patel NR, Demenczuk TM, et al. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J Virol 2004; 78: 3663-3674.
12. Lau SK, Yip CC, Tsoi HW, et al. Clinical features and complete genome characterization of a distinct human rhinovirus (HRV) genetic cluster, probably representing a previously undetected HRV species, HRV-C, associated with acute respiratory illness in children. J Clin Microbiol 2007; 45: 3655-3664.
13. Lee WM, Kiesner C, Pappas T, et al. A diverse group of previously unrecognized human rhinoviruses are common causes of respiratory illnesses in infants. PLoS One 2007; 2: e966.
14. Greve JM, Davis G, Meyer AM, et al. The major human rhinovirus receptor is ICAM-1. Cell 1989; 56: 839-847.
15. Hofer F, Gruenberger M, Kowalski H, et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc Natl Acad Sci USA 1994; 91: 1839-1842.
16. Couch RB. Rhinoviruses. In: Fields BN, Knipe DM, Mowley PM, et al., eds. Fields Virology. 3rd Edn. Philadelphia, Lippincott-Raven Publishers, 1996; pp. 713-734.
17. Rossmann MG, Arnold E, Erickson JW, et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985; 317: 145-153.
18. McCray J, Werner G. Different rhinovirus serotypes neutralized by antipeptide antibodies. Nature 1987; 329: 736-738. (Pubitemid 17151634)
19. Smith TJ. Antibody interactions with rhinovirus. Semler BL, Wimmer E, eds. In: Molecular Biology of Picornaviruses. Washington, ASM Press, 2002; pp. 39-49.
20. Hewat EA, Marlovits TC, Blaas D. Structure of a neutralizing antibody bound monovalently to human rhinovirus 2. J Virol 1998; 72: 4396-4402.
21. Che Z, Olson NH, Leippe D, et al. Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J Virol 1998; 72: 4610-4622. (Pubitemid 28215635)
22. Hadfield AT, Lee W, Zhao R, et al. The refined structure of human rhinovirus 16 at 2.15 Å resolution: implications for the viral life cycle. Structure 1997; 5: 427-441.
23. Verdaguer N, Blaas D, Fita I. Structure of human rhinovirus serotype 2 (HRV2). J Mol Biol 2000; 300: 1179-1194.
24. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993; 307: 982-986.
25. Johnston SL, Pattemore PK, Sanderson G, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996; 154: 654-660.
26. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008; 178: 667-672.
27. Sears MR. Epidemiology of asthma exacerbations. J Allergy Clin Immunol 2008; 122: 662-668.
28. Message SD, Laza-Stanca V, Mallia P, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 2008; 105: 13562-13567.
29. Douglas RG Jr, Couch RB. Attenuation of rhinovirus type 15 for humans. Nature 1969; 223: 213-214.
30. Francis MJ, Hastings GZ, Sangar DV, et al. A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2. J Gen Virol 1987; 68: 2687-2691.
31. Fang F, Yu M. Viral receptor blockage by multivalent recombinant antibody fusion proteins: inhibiting human rhinovirus (HRV) infection with CFY196. J Antimicrob Chemother 2004; 53: 23-25.
32. De Palma AM, Vliegen I, De Clercq E, et al. Selective inhibitors of picornavirus replication. Med Res Rev 2008; 28: 823-884.
33. Skern T, Torgersen H, Auer H, et al. Human rhinovirus mutants resistant to low pH. Virology 1991; 183: 757-763.
34. Fling SP, Gregerson DS. Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. Anal Biochem 1986; 155: 83-88.
35. Focke M, Mahler V, Ball T, et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001; 15: 2042-2044.
36. Niederberger V, Pauli G, Gronlund H, et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. J Allergy Clin Immunol 1998; 102: 579-591.
37. Focke M, Linhart B, Hartl A, et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 2004; 34: 1525-1533.
38. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
39. Stott EJ, Tyrrell DA. Some improved techniques for the study of rhinoviruses using HeLa cells. Arch Gesamte Virusforsch 1968; 23: 236-244.
40. Vlasak M, Roivainen M, Reithmayer M, et al. The minor receptor group of human rhinovirus (HRV) includes HRV23 and HRV25, but the presence of a lysine in the VP1 HI loop is not sufficient for receptor binding. J Virol 2005; 79: 7389-7395.
41. Rossmann MG. The canyon hypothesis. Viral Immunol 1989; 2: 143-161.
42. Verdaguer N, Fita I, Reithmayer M, et al. X-ray structure of a minor group human rhinovirus bound to a fragment of its cellular receptor protein. Nat Struct Mol Biol 2004; 11: 429-434.
43. Colonno RJ, Callahan PL, Leippe DM, et al. Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. J Virol 1989; 63: 36-42.
44. Katpally U, Fu TM, Freed DC, et al. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J Virol 2009; 83: 7040-7048.
45. Kolatkar PR, Bella J, Olson NH, et al. Structural studies of two rhinovirus serotypes complexed with fragments of their cellular receptor. EMBO J 1999; 18: 6249-6259.
46. Lewis JK, Bothner B, Smith TJ, et al. Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci 1998; 95: 6774-6778.